Compare Enveric Biosciences Inc (ENVB) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Roundhill Magnificent Seven ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Roundhill Magnificent Seven ETF trades at $73.42 (market cap $5.84B). The key difference: Roundhill Magnificent Seven ETF is far larger — about 872.9× Enveric Biosciences Inc's market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| ENVB | MAGS | |
|---|---|---|
Market Cap | $6.69M | $5.84B |
Volume | 41,141 | 1,765,091 |
Sector | Health | Sector/Thematic |
52-Week High | $10.80 | $73.90 |
52-Week Low | $1.27 | $55.39 |
Typical Hold Time | 14 Days | 36 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
MAGS (Roundhill Magnificent Seven ETF) trades at $73.69, down 0.28% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides equal-weighted exposure to seven mega-cap tech leaders and has delivered 181% returns since launch, though it trails the S&P 500 in 2026 with just 2% YTD gains. Recent news highlights AI-driven momentum but also concerns about the 'Magnificent Seven' theme fracturing as capital spending pressures dividends and buybacks.
The outlook remains cautiously optimistic given AI supercycle potential, but investors face concentration risk in tech and underperformance versus broader markets. Key risks include aggressive AI spending impacting cash flows and shifting investor preference toward semiconductors. Analyst sentiment is mixed, balancing long-term growth prospects against near-term valuation concerns and market rotation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
